Medication info
Crovatin Tablet 10mg (Rosuvastatin Calcium)

Crovatin Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/Alu-Alu X 2), 30 tablets/bottle
Approval status
Active

MFDS item code 201000985 · Approved 2010.01.28 · Insurance code 698001120

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct to diet and exercise in patients with primary hypercholesterolemia or mixed dyslipidemia when these interventions alone are not effective. It is also used with other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia to control cholesterol levels. In patients with hypercholesterolemia, it helps to lower total cholesterol and bad LDL cholesterol levels, delaying the progression of atherosclerosis. It can be safely used in pediatric patients aged 10 to 17 with familial heterozygous hypercholesterolemia. It is also suitable as an adjunct to diet in patients with primary dysbetalipoproteinemia. Lastly, in adults at high risk for cardiovascular disease, it contributes to reducing the risk of stroke, myocardial infarction, and arterial revascularization. In summary, this medication effectively improves cholesterol levels and cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. Dose adjustments should be made at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to its components, patients with severely impaired liver function, patients with muscle disorders, patients taking certain medications, patients with severe renal impairment, or women who are pregnant or breastfeeding. Additionally, this medication should be used with caution in patients at high risk for muscle-related side effects. These patients include those with moderate to severe renal impairment, hypothyroidism, a family history of muscle disorders, patients with alcohol addiction, and the elderly. As this medication can affect liver function, patients with a history of liver disease or excessive alcohol consumption should undergo regular liver function tests before and during treatment. If symptoms such as muscle pain, muscle weakness, or cramps occur, patients should notify their doctor immediately, and a blood test should be performed to check for muscle damage. If significant muscle damage is present, the medication should be discontinued. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should avoid it. This medication can interact with other medications, so patients must inform their healthcare provider about any other medications they are taking. Caution is needed when combining it with specific antivirals, immunosuppressants, antifungals, and fibrate-class drugs. Women who are pregnant or may become pregnant should use appropriate contraception and should discontinue use immediately if they become pregnant. It is also advisable for breastfeeding women not to use this medication. There is no specific antidote for overdose, so treatment should be based on symptoms, and liver and muscle function tests are necessary. Patients should be cautious as dizziness may occur while driving or operating machinery. Finally, this medication may rarely cause severe skin reactions, liver damage, renal abnormalities, or neurological symptoms in some patients, so they should consult their healthcare provider if any unusual symptoms occur.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, morbilliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, preferably at room temperature between 1 to 30 degrees Celsius. Storing it this way can help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/Alu-Alu X 2), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.